This was the stock's second consecutive day of losses.

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Shares of Ocugen Inc. OCGN rallied 5.49% to $1.04 Tuesday, on what proved to be an all-around great trading session for the ...

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients ...

Ocugen, a company in the healthcare sector, has experienced a notable decline in its stock price over the past week, dropping by 8.62%. Despite this downturn, analysts like Robert ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

Ocugen To Present at BIO International Convention 2025. MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in ...

OCU410ST employs an adeno-associated virus platform for retinal delivery of the RORA gene, targeting Stargardt disease ...

The US Food and Drug Administration (FDA) has approved Ocugen’s investigational new drug (IND) amendment to initiate a Phase ...

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

Summary. Ocugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study.